Eidos Therapeutics (EIDX) stock price, revenue, and financials

Eidos Therapeutics market cap is $1.9 b, and annual revenue was $26.69 m in FY 2019

$1.9 B

EIDX Mkt cap, 03-Jun-2020
Eidos Therapeutics Net income (Q1, 2020)-22.8 M
Eidos Therapeutics EBIT (Q1, 2020)-22.9 M
Eidos Therapeutics Cash, 31-Mar-2020196.5 M
Eidos Therapeutics EV4.7 B

Eidos Therapeutics Income Statement

Annual

USDFY, 2018FY, 2019

Revenue

26.7m

Cost of goods sold

2.5m

Gross profit

24.2m

Gross profit Margin, %

91%

R&D expense

28.5m46.9m

General and administrative expense

9.2m17.8m

Operating expense total

37.8m64.6m

EBIT

(37.8m)(40.5m)

EBIT margin, %

(152%)

Net Income

(40.7m)(37.8m)

Quarterly

USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

26.7m

Cost of goods sold

2.5m

Gross profit

24.2m

Gross profit Margin, %

91%

R&D expense

7.4m7.9m8.5m12.5m12.0m17.6m

General and administrative expense

1.9m2.6m4.0m2.3m6.0m5.3m

Operating expense total

9.3m10.6m12.6m14.8m17.9m22.9m

EBIT

(9.3m)(10.5m)(12.6m)(14.8m)6.3m(22.9m)

EBIT margin, %

23%

Income tax expense

Net Income

(10.6m)(10.2m)(11.7m)(14.1m)6.9m(22.8m)

Eidos Therapeutics Balance Sheet

Annual

USDFY, 2018FY, 2019

Cash

157.1m191.2m

Prepaid Expenses

1.8m4.7m

Current Assets

159.0m195.9m

PP&E

209.0k1.3m

Total Assets

160.1m203.8m

Accounts Payable

2.0m3.2m

Short-term debt

1.5b

Current Liabilities

4.8m10.4m

Long-term debt

16.1m

Total Debt

1.5b

Total Liabilities

5.1m32.4m

Common Stock

37.0k38.0k

Additional Paid-in Capital

220.2m274.5m

Retained Earnings

(65.3m)(103.1m)

Total Equity

155.0m171.4m

Financial Leverage

1 x1.2 x

Eidos Therapeutics Cash Flow

Annual

USDFY, 2018FY, 2019

Net Income

(40.7m)(37.8m)

Depreciation and Amortization

56.0k77.0k

Accounts Payable

1.4m1.2m

Cash From Operating Activities

(33.1m)(31.6m)

Purchases of PP&E

(150.0k)(227.0k)

Cash From Investing Activities

(150.0k)(227.0k)

Cash From Financing Activities

184.9m65.9m

Net Change in Cash

151.7m34.0m

Interest Paid

74.0k

Quarterly

USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

(26.2m)(36.4m)(11.7m)(25.8m)(18.9m)(22.8m)

Depreciation and Amortization

24.0k40.0k15.0k33.0k53.0k27.0k

Accounts Payable

1.2m1.9m1.3m(114.0k)1.6m821.0k

Cash From Operating Activities

(14.8m)(23.7m)(10.1m)(26.1m)(15.1m)(18.9m)

Purchases of PP&E

(129.0k)(144.0k)(35.0k)(147.0k)(51.0k)

Cash From Investing Activities

(129.0k)(144.0k)(35.0k)(147.0k)(51.0k)

Cash From Financing Activities

186.1m184.9m25.0k420.0k24.0m24.3m

Net Change in Cash

171.2m161.1m(10.1m)(25.7m)8.7m5.4m

Interest Paid

518.0k

Eidos Therapeutics Ratios

USDY, 2020

EV/EBIT

-204.9 x

EV/CFO

-248.4 x

Financial Leverage

1.2 x